Thermo Fisher Scientific (NYSE:TMO) Shares Gap Down to $547.25

Thermo Fisher Scientific Inc. (NYSE:TMO)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $547.25, but opened at $534.80. Thermo Fisher Scientific shares last traded at $537.63, with a volume of 340,357 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMO. Raymond James upped their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. The Goldman Sachs Group lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada raised their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Stock Performance

The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The company’s 50 day moving average price is $571.57 and its 200-day moving average price is $527.01. The company has a market cap of $207.31 billion, a PE ratio of 35.42, a price-to-earnings-growth ratio of 2.33 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period in the previous year, the company posted $5.40 earnings per share. The business’s revenue was down 4.9% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.10%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TMO. Savant Capital LLC increased its stake in Thermo Fisher Scientific by 0.5% in the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 18 shares during the last quarter. Sugarloaf Wealth Management LLC grew its stake in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton increased its holdings in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after buying an additional 19 shares during the last quarter. Tsfg LLC raised its position in shares of Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares in the last quarter. Finally, 1776 Wealth LLC grew its position in Thermo Fisher Scientific by 2.4% in the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.